Sangamo Therapeutics shares surge 10.26% premarket after positive Fabry disease gene therapy data and FDA BLA submission progress.

Sangamo Therapeutics surged 10.26% in premarket trading following the announcement of positive clinical data from its registrational STAAR study for isaralgagene civaparvovec in Fabry disease. The study demonstrated a positive mean annualized eGFR slope at 52 weeks across all dosed patients, a key endpoint agreed upon with the FDA for accelerated approval. Additionally, the FDA approved a rolling Biologics License Application (BLA) submission, signaling regulatory progress for the gene therapy candidate. While the company also priced a $25 million underwritten offering, the market appeared to prioritize the clinical and regulatory milestones, which highlight the potential for a transformative, one-time treatment in a high-unmet-need disease. The favorable safety profile and durable clinical benefits further reinforced investor optimism, outweighing dilution concerns from the equity raise.